New glucagon delivery system reduces episodes of post-bariatric surgery hypoglycemia

February 8, 2018, Joslin Diabetes Center
Mary-Elizabeth Patti, MD, FACP, is Investigator in the section on Integrative Physiology and Metabolism at Joslin Diabetes Center, Co-Director of the Advanced Genetics and Genomics Core, Director of the Hypoglycemia Clinic, and Assistant Professor of Medicine at Harvard Medical School. Credit: John Soares

A new "smart" glucagon delivery system created by researchers from the Joslin Diabetes Center and Harvard School of Engineering and Applied Sciences may make it possible for people with post-bariatric hypoglycemia to live free from this dangerous complication. The findings are important because the number of bariatric surgeries is going up and physicians do not have adequate tools to treat this condition. The research appears in the February issue of Diabetes Technology & Therapeutics.

Current treatments for post-bariatric , including a special diet and medications, have their limitations. In recent years, however, a number of innovative advances have opened the door to a new approach.

"One potential way to treat this complication is to use glucagon, a natural hormone made by the body that raises glucose. It is used to treat in patients with diabetes. If we give someone glucagon right before they became hypoglycemic we might be able to prevent hypoglycemia," says study senior author Mary-Elizabeth Patti, MD, FACP, Director of the Hypoglycemia Clinic at Joslin Diabetes Center.

"Essentially, we are combining three new developments into one system that is being used to both prevent and treat hypoglycemia," says Dr. Patti.

The components of this novel system include a continuous glucose monitor (CGM), which is a sensor that checks glucose values every five minutes; an investigational form of glucagon that can be delivered rapidly and precisely through a pump; and a mobile platform (pAPS) that hosts a novel hypoglycemia prediction algorithm developed by the research team from Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) directed by Eyal Dassau, PhD, senior author of the paper.

"The algorithm predicts when a hypoglycemic episode is about to occur and sets off alerts and can automate glucagon delivery," says co-author Alejandro J. Laguna Sanz, PhD, from the Harvard team.

In this preliminary study, the research team tested the system on seven participants diagnosed with post-bariatric hypoglycemia. After the delivery system was placed on the participants, they were given a high carbohydrate liquid meal to induce severe hypoglycemia and were then monitored for many hours.

Investigators used what is called an open system. It beeped when participants were at high risk for hypoglycemia. At that point, an investigator would administer a dose of glucagon.

"This system delivers small, precise doses of stable glucagon, which reverses but does not over-treat episodes of hypoglycemia," says study coauthor Christopher Mulla, MD, Staff Endocrinologist and Postdoctoral Research Fellow at the Joslin Diabetes Center.

Over the course of the study, progressive changes were made to the computer algorithm and the glucagon dosage in order to fine tune the approach. Corrections were made by using earlier hypoglycemia alarms or larger glucagon doses.

The system is feasible and safe, according to investigators. "This is a perfect example of medically-inspired engineering where a team from SEAS is partnering with a clinical team to resolve a major clinical need," says Dr. Dassau.

The single-dose glucagon used in the study was well-tolerated. It raised serum glucagon yet did not provoke increased insulin. This prediction system successfully alerted investigators to impending hypoglycemia, and as the algorithm was refined throughout the study, the amount of time participants experienced hypoglycemia decreased significantly.

"This will provide a new treatment for patients who typically have difficulty recognizing low blood sugars," says Dr. Mulla. "Many of these patients can have hypoglycemia unawareness, which means that they don't know their blood glucose is dropping. Consequently they can become incapacitated and have difficulty treating themselves once they do recognize that they are not feeling well."

While this study tested an open loop system, meaning the investigators had to activate the delivery of the medicine, it has cleared the way for future studies where the closed loop system (the computer algorithm collects the data, detects hypoglycemia, and tells the pump to deliver ) can be used.

Currently the research team is conducting a randomized, double-blind placebo-controlled trial of this system, which aims to show whether the closed loop system can prevent hypoglycemia.

"The system that we are testing now is the one we hope to use in patients as an outpatient treatment," says Dr. Patti.

Explore further: Low-carb diet cuts tx effect of glucagon in hypoglycemia

More information: Alejandro J. Laguna Sanz et al, Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia, Diabetes Technology & Therapeutics (2018). DOI: 10.1089/dia.2017.0298

Related Stories

Low-carb diet cuts tx effect of glucagon in hypoglycemia

November 7, 2016
(HealthDay)—For patients with type 1 diabetes, a low-carbohydrate diet (LCD) results in lower incremental rises in plasma glucose (PG) after mild hypoglycemia compared with an isocaloric high-carbohydrate diet (HCD), according ...

G-pen may aid hypoglycemia with type 1 diabetes

February 22, 2016
(HealthDay)—Mini-dose glucagon administered using a stable, ready-to-use G-Pen Mini glucagon may be an effective option for mild to moderate hypoglycemia in adults with type 1 diabetes, according to a study published online ...

Similar defects ID'd for T2DM, chronic pancreatitis and diabetes

August 2, 2017
(HealthDay)—Patients with type 2 diabetes and those with diabetes secondary to chronic pancreatitis have similarly impaired α-cell responses to oral glucose ingestion and hypoglycemia, according to a study published online ...

Emergency services crews often unprepared for diabetic crises

January 26, 2018
(HealthDay)—If you call 911, you expect to get the medical services you need.

Dasiglucagon well tolerated for severe hypoglycemia

January 3, 2018
(HealthDay)—Dasiglucagon is well tolerated and is associated with an early pharmacodynamic response similar to that of GlucaGen for severe hypoglycemia, according to a study published online Dec. 22 in Diabetes Care.

Acute kidney injury ups risk for post-discharge hypoglycemia

January 18, 2018
(HealthDay)—For hospitalized patients with diabetes, acute kidney injury (AKI) is a risk factor for post-discharge hypoglycemia, according to a study published online Jan. 11 in Diabetes Care.

Recommended for you

Deep brain stimulation found to improve diabetes symptoms

May 24, 2018
A team of researchers from several institutions in the Netherlands and Yale University in the U.S. has found evidence that suggests deep brain stimulation (DBS) can help treat type 2 diabetes. In their paper published in ...

Women with pregnancy-related diabetes may be at risk for chronic kidney disease

May 21, 2018
Gestational diabetes may predispose women to early-stage kidney damage, a precursor to chronic kidney disease, according to a study by researchers at the National Institutes of Health and other institutions. The study appears ...

Diabetes researchers find switch for fatty liver disease

May 17, 2018
Duke researchers have identified a key fork in the road for the way the liver deals with carbohydrates, fats and protein. They say it could be a promising new target for combating the pandemics of fatty liver disease and ...

New study of youth with type 1 diabetes connects 'honeymoon period' with lower LDL cholesterol

May 17, 2018
A new study by UMass Medical School physician-scientist Benjamin U. Nwosu, MD, finds that children with type 1 diabetes who experienced a partial clinical remission, or "honeymoon phase," had significantly lower low-density ...

"Living drug factories" may one day replace injections

May 17, 2018
Patients with diabetes generally rely on constant injections of insulin to control their disease. But MIT spinout Sigilon Therapeutics is developing an implantable, insulin-producing device that may one day make injections ...

Boosting the effects of vitamin D to tackle diabetes

May 10, 2018
More than 27 million people in the United States are living with type 2 diabetes, according to the Centers for Disease Control and Prevention. As the population ages and a growing percentage of people become overweight or ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.